Clinical Trials in Systemic Lupus Erythematosus (SLE)
This is a study for treatment of lupus nephritis using low dose intravenous cytoxan and abatacept (or placebo) for 3 months, followed by oral azathioprine for a total of 2 years. All medications in this study are FDA approved.
Sponsor: National Institute of Allergy and Infectious Disease (NIAID) through the Immune Tolerance Network (ITN)
Participants: Must have a diagnosis of lupus nephritis via a kidney biopsy performed within the past year and greater than 1 gram of protein in the urine.
Contact: Brenda Meier, RN Lupus Clinical Trials Coordinator 919-843-6619
What is the study?
This is a study to evaluate the safety and efficacy of an injectable experimental drug (LY2127399) versus placebo in patients with active systemic lupus erythematosus.
Sponsor:Eli Lilly
Participants:Must have a diagnosis of lupus and active symptoms of disease activity at the time of the screening visit.
Contact: Brenda Meier, RN Lupus Clinical Trials Coordinator 919-843-6619
What is the study?
Clinical Trials in Rheumatoid Arthritis
This is a study that is looking at African Americans with Rheumatoid Arthritis. This study consists of only one study visit and does not involve any medication. The purpose is to study genetic and other factors to learn more about the disease.
Sponsor:National Institute of Heath
Participants:Must be African American with diagnosis of rheumatoid arthritis.
Contact: Diane Bresch, RN, BSN Clinical Trials Coordinator 919-966-0545
What is the study?
This is a study that is assessing the effects of celecoxib, ibuprofen, and naproxen on cardiovascular events in subject with rheumatoid arthritis or osteoarthritis and pre-existing heart disease or at high risk for heart disease. Subjects will be given one of the following medications: celecoxib, ibuprofen or naproxen. These medications are FDA approved.
Sponsor:Pfizer
Participants:Subjects must be 18 years or older and have rheumatoid arthritis or osteoarthritis for at least 6 months duration. Subjects cannot have had an MI or stoke within 3 months of beginning the study.
Contact: Diane Bresch, RN, BSN Clinical Trials Coordinator 919-966-0545
What is the study?
This study is for treatment of rheumatoid arthritis using medication FosD or placebo. Fos D is not approved by the FDA. Subjects must also be taking one of the following: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine. Participation in this study will last for 52 weeks. Subject will have the option of entering open-label phase of the study after 52 weeks to receive active drug until it is FDA approved and available on the market.
Sponsor:AstraZeneca
Participants:Subjects must be 18 or over with a diagnosis of rheumatoid arthritis. Women of childbearing may participate if using acceptable contraceptive methods. Subjects must have active rheumatoid arthritis defined as greater than 4 swollen and 4 tender joints.
Contact: Diane Bresch, RN, BSN Clinical Trials Coordinator 919-966-0545
What is the study?
Clinical Trials in Osteoarthritis
This study involves a single injection of either Bone Morphogenetic Protein or placebo into the knee in patients with osteoarthritis . This is an investigational drug which means it is not approved by the FDA.
Sponsor:Stryker
Participants:MMust be at least 40 years old and ambulatory with osteoarthritis of the knee with symptoms for at least 6 months and pain on the majority of the days in the last 30 days. You must also have radiographic evidence of osteoarthritis. Females subjects must be post menopausal or not capable of childbearing.
Contact: Diane Bresch, RN, BSN Clinical Trials Coordinator 919-966-0545
What is the study?
This is a study that is assessing the effects of celecoxib, ibuprofen, and naproxen on cardiovascular events in subject with rheumatoid arthritis or osteoarthritis and pre-existing heart disease or at high risk for heart disease. Subjects will be given one of the following medications: celecoxib, ibuprofen or naproxen. These medications are FDA approved.
Sponsor:Pfizer
Participants:Subjects must be 18 years or older and have rheumatoid arthritis or osteoarthritis for at least 6 months duration. Subjects cannot have had an MI or stoke within 3 months of beginning the study.
Contact: Diane Bresch, RN, BSN Clinical Trials Coordinator 919-966-0545
What is the study?